Your browser doesn't support javascript.
loading
Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.
Kreuz, Wolfhart; Gill, Joan C; Rothschild, Chantal; Manco-Johnson, Marilyn J; Lusher, Jeanne M; Kellermann, Elke; Gorina, Eduard; Larson, Peter J.
Afiliación
  • Kreuz W; The Center of Pediatrics III, Department of Hematology, Oncology and Hemostaseology, Johann Wolfgang Goethe-University Hospital, Frankfurt am Main, Germany. Wolfhart.Kreuz@kgu.de
Thromb Haemost ; 93(3): 457-67, 2005 Mar.
Article en En | MEDLINE | ID: mdl-15735795
The safety and efficacy of a full-length sucrose-formulated recombinant factor VIII product (rFVIII-FS; Kogenate FS; Kogenate Bayer) was evaluated in previously untreated (PUPs) and minimally treated (MTP) patients with severe haemophilia A (FVIII <2%). Patients (37 PUPs; 24 MTPs) aged 0.1-25.7 months were treated with rFVIII-FS for a cumulative of 9,141 exposure days (EDs), median 114 EDs (range 4-478), on prophylactic or on-demand therapy. Eighty-nine percent of all treated bleeding episodes were successfully treated with 1 (74%) or 2 (15%) infusions. Clinical response to first infusion for each bleeding episode was rated as 'excellent' in 58%, or 'good' in 33%, of all cases. Recombinant FVIII-FS was used in 27 surgical procedures, mainly catheter implantations, which were all conducted without bleeding complications. FVIII recovery mean values (approximately 2%/kg/IU) were as expected for any licensed FVIII concentrate. FVIII neutralizing antibody formation was 15% (9/60). Aside from inhibitor formation, three adverse events were rated as 'at least possibly drug-related' for a total drug-related adverse event rate of 0.14%. No viral seroconversions were observed. Overall, excellent safety and efficacy were demonstrated with rFVIII-FS for therapy of young children with severe haemophilia A.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factor VIII / Hemofilia A Tipo de estudio: Clinical_trials Límite: Child, preschool / Humans / Infant Idioma: En Revista: Thromb Haemost Año: 2005 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Alemania
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factor VIII / Hemofilia A Tipo de estudio: Clinical_trials Límite: Child, preschool / Humans / Infant Idioma: En Revista: Thromb Haemost Año: 2005 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Alemania